Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Whitworth

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Plos One|September 13, 2012
Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube testsWilliam C Whitworth, Lanette R Hamilton, Donald J Goodwin, et al.
Journal of Clinical Microbiology|October 14, 2016
Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine ExposureA Jayakumar, R M Savic, C K Everett, et al.
Plos One|December 2, 2011
Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigensKathryn L Kellar, Jennifer Gehrke, Stephen E Weis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Tuberculosis Research and Treatment|April 17, 2014
Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa ApplicantsStella O Chuke, Nguyen Thi Ngoc Yen, Kayla F Laserson, et al.
Contemporary Clinical Trials|March 13, 2021
Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosisKia E Bryant, Yan Yuan, Melissa Engle, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Plos One|September 13, 2012
Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube testsWilliam C Whitworth, Lanette R Hamilton, Donald J Goodwin, et al.
Journal of Clinical Microbiology|October 14, 2016
Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine ExposureA Jayakumar, R M Savic, C K Everett, et al.
Plos One|December 2, 2011
Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigensKathryn L Kellar, Jennifer Gehrke, Stephen E Weis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Tuberculosis Research and Treatment|April 17, 2014
Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa ApplicantsStella O Chuke, Nguyen Thi Ngoc Yen, Kayla F Laserson, et al.
Contemporary Clinical Trials|March 13, 2021
Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosisKia E Bryant, Yan Yuan, Melissa Engle, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose RifapentineAnthony T Podany, Michelle Pham, Erin Sizemore, et al.
Pageof 8